清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis

医学 溃疡性结肠炎 安慰剂 内科学 胃肠病学 随机对照试验 临床终点 临床试验 外科 病理 替代医学 疾病
作者
Shenghong Zhang,Baili Chen,Bangmao Wang,Hong Chen,Yan Li,Qian Cao,Jie Zhong,Ming‐Jium Shieh,Zhihua Ran,Tongyu Tang,Ming Yu Yang,Beibei Xu,Qiang Wang,Yunjie Liu,Lijia Ma,Xiaolin Wang,Nan Zhang,Su Zhang,Wenyu Guo,Liang Huang
出处
期刊:JAMA [American Medical Association]
卷期号:329 (9): 725-725 被引量:107
标识
DOI:10.1001/jama.2023.1084
摘要

Importance: Olamkicept, a soluble gp130-Fc-fusion-protein, selectively inhibits interleukin 6 (IL-6) trans-signaling by binding the soluble IL-6 receptor/IL-6 complex. It has anti-inflammatory activities in inflammatory murine models without immune suppression. Objective: To assess the effect of olamkicept as induction therapy in patients with active ulcerative colitis. Design, Setting, and Participants: Randomized, double-blind, placebo-controlled phase 2 trial of olamkicept in 91 adults with active ulcerative colitis (full Mayo score ≥5, rectal bleeding score ≥1, endoscopy score ≥2) and an inadequate response to conventional therapy. The study was conducted at 22 clinical study sites in East Asia. Patients were recruited beginning in February 2018. Final follow-up occurred in December 2020. Interventions: Eligible patients were randomized 1:1:1 to receive a biweekly intravenous infusion of olamkicept 600 mg (n = 30) or 300 mg (n = 31) or placebo (n = 30) for 12 weeks. Main Outcomes and Measures: The primary end point was clinical response at week 12 (defined as ≥3 and ≥30% decrease from baseline total Mayo score; range, 0-12 [worst] with ≥1 decrease and ≤1 in rectal bleeding [range, 0-3 {worst}]). There were 25 secondary efficacy outcomes, including clinical remission and mucosal healing at week 12. Results: Ninety-one patients (mean age, 41 years; 25 women [27.5%]) were randomized; 79 (86.8%) completed the trial. At week 12, more patients receiving olamkicept 600 mg (17/29 [58.6%]) or 300 mg (13/30 [43.3%]) achieved clinical response than placebo (10/29 [34.5%]), with adjusted difference vs placebo of 26.6% (90% CI, 6.2% to 47.1%; P = .03) for 600 mg and 8.3% (90% CI, -12.6% to 29.1%; P = .52) for 300 mg. Among patients randomized to receive 600 mg olamkicept, 16 of 25 secondary outcomes were statistically significant compared with placebo. Among patients randomized to receive 300 mg, 6 of 25 secondary outcomes were statistically significant compared with placebo. Treatment-related adverse events occurred in 53.3% (16/30) of patients receiving 600 mg olamkicept, 58.1% (18/31) receiving 300 mg olamkicept, and 50% (15/30) receiving placebo. The most common drug-related adverse events were bilirubin presence in the urine, hyperuricemia, and increased aspartate aminotransferase levels, and all were more common in the olamkicept groups compared with placebo. Conclusions and Relevance: Among patients with active ulcerative colitis, biweekly infusion of olamkicept 600 mg, but not 300 mg, resulted in a greater likelihood of clinical response at 12 weeks compared with placebo. Further research is needed for replication and to assess longer-term efficacy and safety. Trial Registration: ClinicalTrials.gov Identifier: NCT03235752.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
把饭拼好给你完成签到 ,获得积分10
4秒前
思源的应助被Agan采纳,获得10
6秒前
好运连连完成签到,获得积分10
47秒前
51秒前
54秒前
五月完成签到,获得积分10
54秒前
瘦瘦的枫叶完成签到 ,获得积分10
57秒前
sugar发布了新的文献求助10
59秒前
传奇3的应助被wuyy采纳,获得10
1分钟前
酷波er的应助被sugar采纳,获得10
1分钟前
Omarkyarm完成签到,获得积分10
1分钟前
1分钟前
wuyy发布了新的文献求助10
1分钟前
圆月弯刀完成签到 ,获得积分10
1分钟前
合适乐巧完成签到 ,获得积分10
1分钟前
null的应助被mashibeo采纳,获得10
1分钟前
wuyy完成签到,获得积分20
1分钟前
赘婿的应助被wuyy采纳,获得10
1分钟前
2分钟前
wuyy发布了新的文献求助10
2分钟前
JUN完成签到,获得积分10
2分钟前
2分钟前
瞿人雄完成签到,获得积分10
2分钟前
没心没肺完成签到,获得积分10
2分钟前
keggin完成签到,获得积分10
2分钟前
2分钟前
alex的应助被科研通管家采纳,获得10
2分钟前
alex的应助被科研通管家采纳,获得10
2分钟前
2分钟前
CHENG驳回了李健的应助
2分钟前
11发布了新的文献求助10
3分钟前
田様的应助被shiqiyuan采纳,获得10
3分钟前
清风完成签到,获得积分10
3分钟前
3分钟前
LeonQiao发布了新的文献求助10
3分钟前
3分钟前
orixero的应助被小文同学采纳,获得10
3分钟前
4分钟前
CHENG发布了新的文献求助40
4分钟前
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195184
求助须知:如何正确求助?哪些是违规求助? 9580915
关于积分的说明 21872990
捐赠科研通 7795171
什么是DOI,文献DOI怎么找? 3437967
关于科研通互助平台的介绍 2561276
邀请新用户注册赠送积分活动 2484678